ESMO 2024 preview – Astellas unveils its KRAS degrader
ASP3082 grabs some early attention among degraders set to feature at ESMO.
Novartis drops out of KRAS
While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.
The Revolution is here, and it’s... confusing
The group reaffirms pancreatic cancer promise with RMC-6236, but has it found the best dose?
Ideaya socks it to GSK
Two years after being snubbed by GSK, Ideaya shows the promise of MAT2A inhibition.
Apollomics shifts to a smaller niche
The group abandons plans in lung cancer with Met exon 14 skipping, to focus on Met amplifications.
Merck KGaA’s xevinapant gets SMACked down
One of the German group’s biggest cancer hopes has fallen flat, raising more questions about targeting an apoptosis pathway.
The predictable failure of trilaciclib
The CDK4/6 inhibitor flunks its phase 3 study – a result that should have been foreseen five years ago.
